News and Events

New clinical trial will determine if gliomas respond to immunotherapy

Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.

Artistic rendering of a T cell immersed in the tumor microenvironment exposed to high levels of potassium

Harnessing T-cell “stemness” could enhance cancer immunotherapy

A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment.

Micrograph of a diffuse large B cell lymphoma

Trial results show that younger lymphoma patients respond well to ibrutinib

A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older.

Louis Staudt elected as a fellow of the AACR Academy

Louis Staudt, M.D., Ph.D., Co-Chief of the Lymphoid Malignancies Branch, was elected to the 2019 class of fellows of the American Association for Cancer Research (AACR) Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer, and to leverage the expertise of the global brain trust of fellows of the AACR Academy to advance the mission of the AACR to prevent and cure all cancers through research, education, communication and collaboration.

New clinical trial recruits the immune system to attack chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells.

Samples from acute myeloid leukemia patients with the splicing factor mutation

CCR researchers discover how protein translation disruptions can lead to cancer

A mutation in the gene U2AF1, which codes for a protein involved in cutting out key pieces of RNA, can also have widespread effects on the translation of messenger RNA into proteins. A close look at one affected protein, interleukin 8 (IL8), revealed increased production as a result of the mutation, leading to inflammation and cancer spread.

Drug found effective in mice for uveal melanoma

Drugs that directly target the transcription factor YAP, which is associated with the growth of uveal melanoma, are too toxic to be used in patients. A new study in mice, however, finds a new, safe and effective way for targeting the YAP pathway.

Elaine Jaffe inducted as honorary fellow of the Royal College of Pathology of Australasia

Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, was recently inducted as an honorary fellow of the Royal College of Pathology of Australasia. The fellowship recognizes the work and publications of a haematophathologist that have influenced and improved haematopathology practice worldwide.

CCR Presentations at AACR - 2019

The American Association for Cancer Research (AACR) Annual Meeting covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. The 2019 AACR Meeting, "Integrative Cancer Science • Global Impact • Individualized Patient Care", will be held in Atlanta, between March 29 - April 3, 2019. View the list of CCR presentations...

From father to daughter: A bone marrow transplant for GATA2 deficiency

James and Jahleel are a father-daughter duo from Tennessee who came to NIH for Jahleel’s bone marrow transplant. Jahleel was diagnosed with GATA2 deficiency, a rare genetic disease that causes a wide range of symptoms, including myeloid leukemias.

Breadcrumb